Introduction
Accurate staging of prostate cancer is essential for the correct selection of therapy, and, together with an assessment of the Gleason score, also affords important prognostic information. Unfortunately, in spite of many recent advances, the precision with which an individual suffering from prostate cancer can be staged pre-operatively is still sub-optimal. The underlying reason for this is that extracapsular extension (ECE) of the tumour is generally microscopic rather than macroscopic. Recent progress has been made, however, and future technological advances, particularly in the ®eld of molecular staging, hold the promise of allowing clinicians to distinguish with greater accuracy those patients with truly localised disease, who are most likely to bene®t from radical therapy, from those with more advanced disease, in whom systemic or endocrine therapy is more likely to be bene®cial.
Digital rectal examination in the staging of prostate cancer
For many decades, digital rectal examination (DRE) has been the cornerstone of the local staging of prostatic cancer. DRE may estimate the local extension of disease, namely stage, but lacks sensitivity and speci®city to determine either tumour volume or the presence or absence of extraprostatic extension of prostate cancer. In general, DRE underestimates both the extent of intracapsular cancer and focal extracapsular invasion. Therefore, distinction between T2a, T2b and T2c based on DRE is often unreliable. The same is true in separating T2 from T3 tumours. In this regard, suspected in®ltration of the prostate landmarks such as the lateral sulci and median furrow, as well as induration of the base of the seminal vesicle as noted by a carefully performed examination may provide important staging information, but may sometimes suggest extracapsular extension when none in fact is present. Only locally extensive T3 tumours can be reliably staged by DRE. This ®nding prompts complementary tests such as ultrasound-guided tissuesampling to con®rm, for example, seminal vesicle invasion. By contrast, DRE is of little value for patients with stage T1 and particularly those patients whose tumours were exclusively discovered by an elevated serum PSA (stage T1c), since, by de®nition, no DRE abnormality is present.
Prostate speci®c antigen and staging
It would be most convenient if the serum PSA value were capable of providing an accurate quantitative re¯ection of prostate tumour volume, and, by extension, an estimate of tumour stage. But how well does serum PSA in fact correlate with the clinical stage? In one study of 553 patients presenting with various stages of prostate cancer, serum PSA was elevated in 447 cases (81%). The percentage of patients with elevated serum PSA increased progressively by stage. Serum PSA exceeded 4.0 ng/ml in 63% of patients with stage A, 72% with stage B, 81% stage C; and 88% stage D. Hudson et al 1 also found that serum PSA increased progressively with clinical stage. However, considerable overlap in clinical stages has been observed in these and other studies. Serum PSA is thus not suf®-ciently reliable for precisely determining clinical stage on an individual patient basis.
Data for pre-operative serum PSA and post-operative pathological stage demonstrate similar imprecision. 2 Serum PSA certainly increases with advancing pathological stage. 3 But, when correlating PSA and clinical stage, tremendous overlap is found in PSA values for all pathological stages. Higher pre-operative serum PSA is not necessarily indicative of extracapsular extension, and lower values do not necessarily imply that a cancer is, in fact, con®ned to the prostate gland. Oesterling et al 4 found false positive rates of PSA as a predictor of extracapsular extension as 74% and 65% for a cut-off level of 4.0 ng/ml and 10.0 ng/ml, respectively. Nevertheless, pre-operative serum PSA can provide some useful predictive information on pathological stage. In a review of more than 925 patients who underwent radical prostatectomy, Kleer et al 5 observed 70% with PSA value`2.0 ng/ml to have organ con®ned disease. At PSA values of 50 ng/ml, 82% had positive surgical margins or positive pelvic lymph nodes, or both. The predictive value of PSA has been shown to be enhanced by taking into account clinical stage, as well as the pathological features of a cancer in biopsy specimens. Using a statistical model that combines clinical stage and tumour grade on biopsy with serum PSA, Partin et al 6 plotted a probability curve for predicting the degree of tumour extension at the time of surgery.
Furthermore PSA values also give useful guidance as to the probability of the presence or absence of bone metastases. Oesterling et al 4 investigated 2064 consecutive patients with prostate cancer, 853 of whom had newly diagnosed, untreated and serum PSA`20 ng/ml at presentation. Out of 852 patients, 7 (0.8%) had a positive bone scan and of these, 4 had a serum PSA b 10 ng/ml and 5 had signi®cant skeletal symptoms. The 95% upper con®dence limit for the false-negative rate is thus approximately 1.5%.
The current position is then that the serum PSA value alone (and for that matter the ratio of free to total PSA) is inadequate for predicting clinical and pathological stages on an individual basis. However some prediction of the ®nal pathological stage is possible by serum PSA, especially taking also into consideration other factors, such as clinical stage and the pathological features of cancer of biopsy specimens.
Molecular staging of prostate cancer
In 1993 Kary Mulis won the Nobel prize for the invention of the polymerase chain reaction (PCR) and it soon became clear that there might be a role for this novel technique in staging patients with clinically localised prostate cancer. The molecular technology of interest was the reverse transcriptase-polymerase chain reaction (RT-PCR). 7 RT-PCR can be used to identify cells expressing certain speci®c genes; in the case of prostate cancer the most obvious gene of interest is PSA. The RT-PCR technique involves preparing RNA sample and reverse transcribing it into DNA. Following this, speci®c cDNAs can be ampli®ed by the use of primers that are speci®c for the particular gene of interest.
Deguchi et al 8 detected mPSA encoding for PSA in the lymph nodes from patients with prostate cancer. Their RT-PCR method could detect as little as 500±5000 copies of mRNA. Morento et al 9 and Jaakkola et al 10 suggested that all patients with early prostate cancer were negative for PSA mRNA by PCR, but 50±70% of patients with proven metastases were also negative. This they attributed to either methodological problems or loss of PSA producing capacity of poorly differentiated prostate cancer cells.
By contrast, in a study reported by Olsson, 11, 12 RT-PCR employed to evaluate the presence of messenger RNA (mRNA) for PSA performed more favourably. The PSA primers were designed to isolate a cDNA fragment of the PSA gene containing 710 base pairs.
To ensure that the cDNA fragment being ampli®ed was indeed a fragment of the PSA gene, the cDNAs recovered from both human prostate cell line (LNCaP) preparations, as well as from human prostate cancer specimens, were isolated and sequenced. In each instance, the cDNA was identical to the sequence of the PSA gene overlapping three of its six exons. The sensitivity of the assay developed was tested by examining serial dilutions of an LNCaP tissue culture diluted with cultured B lymphocytes. The initial assay sensitivity allowed the detection of one prostate cancer cell diluted in 10 6 white cells. One hundred and thirty-eight patients with clinically localised prostate cancer, scheduled to undergo radical retropubic prostatectomy, were studied. A blood sample was taken from each patient pre-operatively. A comparison was made between the results of the RT-PCR assay and the histology review. Of the 138 cases, 54 (39%) exhibited extraprostatic extension of prostate cancer. Forty patients (29%) were judged to be potential surgical failures, as de®ned by a positive surgical margin or seminal vesicle involvement. A total of 98 patients (71%) had specimencon®ned disease, including 84 (61%) who had organcon®ned cancer. The RT-PCR assay prior to radical prostatectomy was negative in 94 patients (68%) and positive in 44 (32%). In patients with capsular perforation, the assay was positive in 74% of cases, and in seminal vesicle invasion, the assay was positive in 67% of cases. Overall, of the 40 patients with pathological ®ndings suggestive of potential surgical failure, 70% had a positive pre-operative RT-PCR assay.
The ability of the RT-PCR assay to predict potential surgical failures was compared with that of imaging, DRE, pre-operative serum PSA levels, as well as the Gleason score. The break points analysed for PSA and Gleason score were standard: less than 10 ng/ml vs more than or equal to 7. In patients who experienced potential surgical failure (those with positive margins or seminal vesicle involvement), the RT-PCR assay had positive and negative predictive values of 64 and 87%, respectively. This compared favourably with similar values for imaging (23 and 72% respectively), DRE (9 and 73% respectively), and Gleason score (41 and 81% respectively). It was concluded by this group that the blood assay using RT-PCR for PSA was a potentially useful staging modality in this group of patients.
Another possible target for the molecular staging of prostate cancer is prostate speci®c membrane antigen (PSMA). This is a glycoprotein of molecular weight 100 000. Several groups have investigated RT-PCR detection of PSMA in the bloodstream of prostate cancer patients. Loric et al 13 found that the detection of PSMA was more often positive for PSMA than PSA in both patients with localised and metastatic disease, as did Isreali et al. 9 By contrast, Cama 12 achieved higher detection rates with PSA than PSMA.
Several controversial issues remain unresolved. The ®rst involves the signi®cance of positive circulating RT-PCR signals and whether they truly represent malignant spread. Tumour biology predicts that most carcinomas shed millions of cells into the circulation before the primary tumour is clinically detectable. Furthermore, the biological signi®cance of circulating tumour cells is unclear. Intravasation of tumour cells into the circulation is just one of a multistep process that ultimately results in symptomatic metastatic disease. Such cells must not only enter the circulation but also must survive long enough to establish a metastatic colony and then to proliferate and ourish at that site.
With the advent of RT-PCR technology, the detection of circulating prostate-derived cells has new possibilities. However, whether such signals represent hitherto undetected circulating benign cells or actively metastasizing neoplastic elements remains to be elucidated. The presence of circulating neoplastic cells does not necessarily equate with either clinically signi®cant metastatic disease or a poor prognosis. Furthermore, patients undergoing prostate needle biopsy, radical prostatectomy and cystoscopy often have evidence of transient circulating signals that eventually clear from the circulation.
At present, no de®nitive conclusions on the utility of RT-PCR molecular staging for prostate cancer can be reached. It is a powerful scienti®c technique that will, no doubt, help to resolve many currently unknown aspects of prostate cancer growth and development. Because positive RT-PCR results do often correlate with known metastatic disease, and since positive results are rare in patients without prostate cancer, positive signals in a patient with pathologically localized prostate cancer could potentially indicate evidence of early metastatic disease or portend early treatment failure. However, only with prolonged follow-up and larger study populations will the true signi®cance of circulating prostatetissue-derived cells be determined. Until that time, in the authors' opinion, RT-PCR molecular staging assays should remain an investigational tool only and are certainly not suf®ciently re®ned to be employed in decisionmaking in the clinical management of men with prostate disease.
Transrectal ultrasound
Transrectal ultrasound (TRUS) by itself is only of limited value as a means of staging prostate cancer.
14 However, bulging or irregularity of the boundary echo adjacent to a peripheral zone hypoechoic lesion may be a feature of ECE 15, 16 ( Figure 1 ). Invasion of the seminal vesicles may occasionally be apparent on TRUS. 17 Extensive ECE is generally regarded as a contraindication for radical prostatectomy because of the very high incidence of positive margins and subsequent disease relapse. Sometimes, however, neo-adjuvant hormonal downstaging or a more extensive procedure, including excision of the neurovascular bundle adjacent to the ECE, might enable the surgeon to achieve complete tumour removal. More usually radiotherapy is employed. Although TRUS in isolation may sometimes determine the presence of ECE, it is now apparent that the careful consideration of DRE ®ndings and PSA values in conjunction with TRUS can achieve a higher speci®city in the identi®cation of extracapsular extension. The main contemporary value of TRUS in this respect is to allow accurate guidance of the automated biopsy device to achieve pathological information. In the future, however, the use of image enhancers looks set to permit more accurate local staging of prostate cancer with this modality.
TRUS-guided prostatic biopsy
Histological con®rmation of prostate cancer is an important prerequisite before initiating treatment for prostate cancer. A number of different biopsy techniques have been used. Digital guidance can be used to direct biopsy of palpable lesions via either the transrectal or transperineal routes. However, TRUS guidance has been shown to be superior digital guidance in directing biopsy of both palpable and impalpable prostate cancers. Recently it has become clear that the information from TRUS guided biopsies are of considerable additional bene®t in staging prostate cancer. There has been some discussion regarding the optimum route for biopsy. The transperineal route carries the advantage that it is less likely to introduce infection, but the disadvantages of Pre-treatment staging of prostate cancer RS Kirby requiring local anaesthesia and less easy guidance with the TRUS probe. In contrast, the transrectal route can be utilised without the need for injection of local anaesthesia and can be guided accurately through the biopsy port incorporated in the TRUS probe. It is now standard practice to administer a broad-spectrum antibiotic prior to biopsy and to give a subsequent course of oral antibiotics, usually of the quinolone variety, after the biopsy. This reduces infective complications to less than 2%. Although the alternative technique of ®ne-needle aspiration has been advocated by some, the cellular aspirate is sometimes dif®cult to interpret cytologically, resulting in false negative ®ndings. A study comparing aspiration cytology with core biopsy in 30 patients with prostate cancer showed that while core biopsy made the correct diagnosis in all cases there was a false positive rate of 30% for aspiration cytology. 18 At present therefore most prostatic biopsies are taken using an automatic biopsy device.
The number of positive biopsies, for example 4 out of 6, their Gleason score and especially the presence or absence of seminal vesicle invasion, as determined by biopsies guided to the base of these structures, are all useful predictors of the eventual pathological stage of prostate cancer.
Neovascularity as a staging tool
A most promising new technique for predicting prostate cancer tumour extent relies on the quanti®cation of tumour angiogenesis or microvessel density (MVD). MVD is a quantitative measurement of the number of small blood vessels within a given area of tissue on a histological slide. It is well known that, in order to grow larger than 1 mm 2 in area, cancers must recruit new blood vessels from the host, and this neovascularity can be readily identi®ed by immunohistochemistry in formalin®xed paraf®n-embedded tissue using an antibody to human von Willebrand factor (factor VIII-related antigen). An association between a high degree of neovascularization and lowered patient survival, has been observed in studies of patients with cancers of the bladder, brain, breast, cervix, endometrium, stomach, head and neck, lung, melanocytes, oral cavity, ovary, rectum, testis and prostate. The following factors, probably acting in concert, are the likely reasons for this association: MVD satis®es many criteria for being a useful biomarker in prostate cancer. In combination with Gleason score and serum PSA, it signi®cantly increases the predictive accuracy for pathological stage and potential outcome. Brawer et al 19 found that the addition of MVD to a Gleason score/PSA model increased its ability to identify extraprostatic extension correctly, from 53±85%.
Most recently, optimised microvessel density (OMVD) as a predictor of extraprostatic extension has been the subject of a multicentre study of 186 patients by Bostwick et al, 20 utilising computer-enhanced image analysis. The study concluded that the prediction of extraprostatic extension was signi®cantly improved when OMVD was incorporated in a logistic regression model with the Gleason score from the diagnostic biopsy and the prebiopsy serum PSA value. For example, a patient with a Gleason score of 7 and a PSA value of 8 had a 53% probability of extraprostatic extension. Adding OMVD to the model distinguished between probabilities of 37 and 89% for the same patient. With a given Gleason score and PSA value, the study indicated that the odds of extraprostatic extension increased 5.97 times with every unit change of log OMVD.
The value of CT scan and staging prostate cancer By contrast, the clinical utility of computed tomography (CT) in the staging of prostate cancer has generally been disappointing. 21 CT has proven to be of little or no value in the assessment of the local disease. It is not capable of distinguishing between prostate cancer from benign conditions in the prostate and is unable to reliably identify extracapsular penetration or seminal vesicle invasion. It would not appear to provide much additional information to that obtained by digital rectal examination or transrectal ultrasound for the staging of local disease.
There has been interest in the use of CT to identify the presence of lymphadenopathy in the pelvis. However, because of the current low incidence of positive lymph nodes, the utility of CT in this situation is almost negligible. Most nodal metastases are microscopic and do not enlarge or distort the lymph nodes. There probably are subsets of patients in whom risk for grossly positive nodes might be higher. A PSA in excess of 25±35 ng/ml or a poorly differentiated tumour (Gleason score b 7 on biopsy) may identify a risk for gross involvement and justify a CT scan. It is important to note that an enlarged lymph node is identi®ed on CT, a CT guided aspiration biopsy is necessary to con®rm the presence of malignancy.
It has been estimated that as much as $75 million could be saved annually in the United States alone by eliminating CT in patients with a PSA less than 10 ng/ml. An even larger amount of money could be saved worldwide with an even more restrictive use.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a new and rapidly advancing, but expensive, technique that utilises a magnetic ®eld, rather than ionising radiation, to produce images of startling clarity. MRI scanners are capable of producing images in the transverse axial, coronal and sagittal planes, and endorectal probes are available for enhanced de®nition.
On T1-weighted images it is not possible to demonstrate the internal architecture of the prostate although a clear demarcation is apparent between the prostate and seminal vesicles and the surrounding fat. By contrast T2-weighted MRI images are able to demonstrate the internal architecture of the prostate. Typically the peripheral zone of the prostate returns high intensity signals whilst prostate cancer produces relatively low intensity signals. However, most other abnormalities within the prostate such as`adenomas', corpora amylacea and prostatitis also return low intensity signals so that unfortunately MRI is not especially accurate at identifying localised prostate cancer. Disappointingly MRI has not proven very much more accurate than TRUS in local staging of prostate cancer. 22 However, supplementation of transverse axial scans with coronal and sagittal scanning has been shown to enhance local staging accuracy from 61±83%. Extracapsular extension is likely if there is apparent asymmetry, irregularity or breaching of the peri-prostatic fat which, unlike the prostate itself, sends low intensity signals. Seminal vesicle invasion is suggested if there are areas of asymmetric low intensity within the normally high intensity vesicles.
A recent multicenter trial comparing MRI with TRUS in the staging of localised prostate cancer concluded that there was no statistically signi®cant difference between the two.
There undoubtedly exists the prospect of more accurate staging of localised prostate cancer. Ever improving endorectal MRI surface coils are currently being evaluated. 23, 24 The images of the internal architecture of the prostate produced from these devices are of exceedingly high quality (Figure 2 ). It seems likely that endorectal MRI scanning will prove to be more accurate than current techniques in the local staging of prostate malignancy, although cost constraints will always limit their availability for every patient.
The role of radionuclide bone scans and correlative imaging studies in the staging of prostate cancer
The axial skeleton is the favoured location for prostate cancer metastases (Figure 3 ). This`bone homing' mechanism, a direct consequence of complex prostate epithelialbone stromal interactions, has made it routine clinical practice to include a radionucleide bone scan and correlative imaging studies in routine prostate cancer staging. Recent literature, however, has questioned the utility of the clinical information gained from radionucleide imaging and correlative radiographs for staging of prostate cancer, especially when examined from the perspective of cost-effectiveness. Typically, men with suspected prostate cancer undergo a digital rectal examination, serum prostate speci®c antigen (PSA) measurement, and transrectal ultrasound with biopsy of the prostate. Routine skeletal imaging has been shown to be unnecessary in a signi®-cant proportion of men with prostate cancer, with most studies advocating the application of radionucleide bone scan and correlative imaging to a more selective paradigm.
Radionucleide imaging was developed in 1963 and remains the gold standard for evaluation of patients with suspected skeletal metastases. This modality is quite sensitive in terms of identifying metastases. Radionucleide imaging is far superior to clinical evaluation, radiographs, or serum alkaline phosphatase, in the detection of occult metastases. False negative scans are reported in less than 1% of patients with con®rmed Pre-treatment staging of prostate cancer RS Kirby bone metastases, though false positive scans are more common. False positive studies, due to previous trauma, degenerative disease, or metabolic abnormalities, may at times be discerned on the basis of the appearance of the lesion(s) on the scan. Radionucleide bone scans re¯ect osteoblastic activity in areas of cortical bone with increased bone turnover. Similarly, plain radiographs re¯ect the calcium content of cortical bone which is altered at the site of clinical metastases. Neither radionucleide imaging nor radiography is capable of imaging bone marrow, thought to be the initial site of prostate metastatic growth, which is then followed by cortical involvement later in the natural history of the lesion. Plain radiographs are the least sensitive in evaluating the axial skeleton for metastases. Fifty percent of bone mineral content must be altered by the metastatic process before a lesion can be detected radiographically. Radionucleide bone scans can show lesions 3±6 months before there is radiologic evidence of metastatic disease. Magnetic resonance imaging (MRI) has shown promise for evaluation of the bone marrow, detecting occult skeletal metastases missed by radionucleide imaging in certain areas of the axial skeleton. Still radionucleide imaging must be regarded as the ®rst-line modality when osseous metastases are suspected, with plain radiographs or MRI serving a more corroboratory role. Chybowski and associates 25 were the ®rst to produce evidence that radionucleide imaging of the skeleton might be unnecessary in a signi®cant proportion of men presenting with clinically localised prostate cancer. In this retrospective study, serum PSA level was a powerful predictor for the presence of osseous metastasis. Fewer than 1% of patients with a PSA level less than 20 ng/ml had a positive bone scan. No patient with a PSA level less than 15 ng/ml had a positive scan. This ®nding was con®rmed by Oesterling, 26 who demonstrated a positive bone scan rate of 0.8% in patients with a PSA level of 20 ng/ml or less. No patient in the study with a PSA level of 10 ng/ml or less had a positive bone scan. These studies looked at the contribution of tumour grade, clinical stage, and acid phosphatase level, to the positive predictive value of the serum PSA level and demonstrated no signi®cant bene®t over PSA level alone in predicting a positive radionucleide scan. The authors concluded that a radionucleide bone scan was unnecessary in men who present with prostate cancer and a PSA level of 10 ng/ml or less, which nowadays represents more than 40% of men with newly diagnosed prostate cancer. Although it must be borne in mind that occasional exceptions to this rule will be seen. 27 The role of radionucleide bone scans in patients with known metastatic disease has also been studied. While not quantitative, the bone scan does assess the number and location of osseous metastases. Studies show that radionucleide imaging provides prognostic information as well as predicts the duration of response to hormonal ablative therapy. Patients who have metastatic disease limited to the pelvis and lumbar spine, with a limited number of metastatic foci, as determined by radionucleide bone scan, demonstrate a signi®cantly better response to hormonal therapy and have a longer mean survival than patients with more extensive disease at the time of presentation. These studies support the need for radionucleide bone scanning in patients with metastatic disease at presentation, as a means of staging and predicting response to therapy and overall survival.
In summary, recent literature advocates a more selective implementation of radionucleide bone scanning and correlative imaging in the diagnosis and treatment of prostate cancer. For patients with localised disease, the serum PSA level should dictate whether a bone scan is performed in the preoperative evaluation unless there are other risk factors such as bone pain. Patients with clinical evidence of metastatic disease, such as an elevated alkaline or acid phosphatase level, or a signi®cantly elevated PSA level, should still undergo radionucleide bone scanning as an initial imaging modality. If there are positive ®ndings, or clinical suspicion in the face of negative ®ndings, plain radiographs of the area of interest are indicated. However, radiography may not offer much additional information with regard to the presence of metastatic disease until late in the natural history of the lesion. If plain ®lms are equivocal or negative and clinical suspicion is high, an MRI of the area may document the presence or absence of a metastatic focus or foci.
Immunoscintigraphy in prostate cancer
The possibility of demonstrating prostate cancer metastases and the identi®cation of their anatomical distribution and of suspected local recurrence after radical prostatectomy by immunoscanning is of great potential importance, since this can not reliably be done by conventional technetium scanning, CT, MR or US scanning. Immunoscintigraphy, however, has also its limitations. Spatial details are limited, but may be improved by single-photon emission CT (SPECT). Also the imaging of hepatic lesions with Indium isotopes is intrinsically suboptimal because of normal intense liver uptake. A combination of functional and anatomical modalities may be advantageous compared with either modality alone. 28 The advent of monoclonal antibody (MAB) technology has permitted the development of radiolabelled tumour reactive probes that can be used in conjunction with gamma camera imaging equipment. However, the use of MABs for tumour imaging is compromised by the fact that tumour speci®c antigens do not currently exist and all target antigens of practical relevance are also expressed to some degree on other malignant and nonmalignant tissues.
Radioisotopes may be complexed to MABs against either acid phosphatase (PAP) or prostatic speci®c antigen (PSA). The use of MAB against PAP for the immunodetection of metastases is hampered by its rapid removal from the blood and its subsequent sequestration by the liver. To circumvent this a number of studies have utilised iodine 123 29 or Indium labelled 30 monoclonal anti-PAP monoclonal antibody F(ab)2 fragment in studies using lymphatic administration (intraprostatic injection) and/or intravenous injection.
Generally, radioisotopes complexed to MABs against acid phosphatase and F(ab)2 fragment have been disappointing due to lack of speci®city and sensitivity of these cytosol-directed MABs, 31 even though preliminary studies originally looked promising. 29, 30 Radiolabelled MABs raised against prostate cancer cells would have potential for immunoscanning using gamma camera imaging. One such MAB is cytogen 356, a murine immunoglobulin G monoclonal antibody to a glycoprotein antigen, described by Horoszewicz 32 that is localised on the membrane of benign and malignant prostate epithelium that can be bound to an Indium isotope. This antibody is commercially available. It has been investigated in a number of preliminary studies, and so far it seems to be superior to conventional methods to localise overt prostate cancer metastases and local extracapsular growth. 33±35 The results of large phase III studies that are underway are awaited with anticipation.
Cytogen 351 MAB bound to technetium 99 m which has excellent imaging characteristics, also seems to have potential usefulness in demonstrating local primary, secondary or recurrent prostate cancer. 36 Another indirect immunoscintigraphy or`cold spot' immunoscintigraphy has also been used. It utilises 99 m technetium labelled monoclonal murine anti-NCA-95 (a differentiation antigen of granulopoiesis, present on mature granulocytes and their precursors in bone marrow) antibody (an IgG 1 antibody) that binds to NCA-95 (a non-speci®c cross reacting antigen of 95 kD). The anti-NCA-95 MAB immunoscintigraphy provides a homogeneous radionucleide image of the bone marrow, where metastases can be seen as cold spots. 37 
Lymphangiography
Pedal lymphangiography was once a popular technique for imaging pelvic lymph nodes. However, the technique is invasive, uncomfortable for the patient, time-consuming and carries the risk of morbidity from pulmonary embolism due to the lipid based contrast medium. With the advent of CT and MRI scanning the use of lymphangiography has virtually fallen into abeyance. Nevertheless lymphangiography, by examining the internal architecture of lymph nodes, does provide images that cannot be duplicated by other techniques, although metastases must be at least 5 mm in diameter to be detectable. Good images can be obtained of the external iliac, common iliac and para-aortic nodes, but doubt has been cast upon the ability of lymphangiography to adequately image the hypogastric and obturator nodes, which are precisely those which become involved earliest in the natural history of metastatic prostate cancer. The accuracy of lymphangiography has been tested in 40 patients who subsequently underwent open pelvic lymphadenectomy as a staging manoeuvre for prostate. Lymphangiography produced a false-positive rate of 59% and a false-negative rate of 36%. Most urologists accept that lymphangiography now has little role to play in contemporary clinical practice in staging prostate cancer.
Laparoscopic pelvic lymphadenectomy
As mentioned previously lymph nodes involved by prostate cancer are often indurated but not markedly enlarged, consequently non-invasive imaging has been rather disappointing as a means of accurate evaluation of the obturator and hypogastric lymph nodes. In the past therefore lymph node staging has been performed by an open operation, either as a staging procedure prior to radiotherapy or radical perineal prostatectomy, or as part of radical retropubic prostatectomy. There now exists, however, the possibility of undertaking this procedure using minimally invasive techniques of laparoscopic technology. 38, 39 Laparoscopic pelvic lymphadenectomy (LPLND) is now a feasible option which allows accurate evaluation of the nodal status of patients with minimal attendant morbidity. The post-operative hospital stay is only 24±48 h and most patients return to work within a week.
Clearly, pelvic lymph node dissection is not appropriate for every patient, but should probably be con®ned to individuals with either higher Gleason score ( ! 7) prostate cancer on biopsy or a PSA greater than 20±25 ng/ml who have no other evidence of metastatic disease and who are candidates, by virtue of both their tumour stage and their life expectancy, for curative therapy. Prior to undertaking de®nitive local therapy, especially radical prostatectomy, either by the perineal or retropubic route, it could be argued that the pelvic lymph nodes should be examined for the presence of metastatic cancer, since if the lymph nodes are found to be positive, it is generally considered a sign of disseminated disease and therefore a contraindication to extirpative prostatic surgery.
A further argument in favour of LPLND is that it permits histological lymph node staging in individuals undergoing non-extirpative therapies such as de®nitive external beam radiotherapy, especially those patients in studies where the results are being compared with those of surgery. Lack of staging data in the past have often skewed the results of radiation therapy trials and now this new minimally invasive technique can facilitate more complete pre-treatment staging, allowing more valid comparisons between surgical and radiotherapeutic treatment options to be made.
The advantages of LPLND lie in its accuracy in terms of de®nitive con®rmation of the presence or absence of lymph node involvement and in the short hospital stay. However, since only a small proportion of patients undergoing radical prostatectomy are now found to have positive lymph nodes, and this is nearly always in the patients with larger volume, higher stage tumours with signi®cantly raised PSA values, it seems logical to restrict LPLND to that already dwindling category of case. This will reduce the proportion of cases in whom the lymph nodes would subsequently be found, on histological evaluation, to be negative.
Conclusions
Carcinoma of the prostate is a highly prevalent and insidious disease. Unless early detection strategies are employed most patients will present with cancer that has already spread beyond the con®nes of the gland and is therefore incurable. Early detection by a combination of DRE and PSA testing has been shown to increase the yield of cancers con®ned to the prostate, but as yet there has been no con®rmation in randomised, controlled studies that this in itself reduces the disease-speci®c mortality.
Accurate staging is crucial for the selection of the most appropriate treatment modality. However, pre-operative staging is, as yet, an inexact science. DRE and PSA provide inexact indications of the local stage, but new techniques of molecular staging using PCR technology hold the promise of a more precise method of detecting extracapsular spread. TRUS may provide some indication of capsular or seminal vesicle involvement but TRUSguided biopsies are necessary to provide histological con®rmation. The grading of the biopsies, the percentage of the cores in®ltrated and the presence or absence of microvascular or perineural invasion, as well as seminal vesicle invasion, are all useful ancillary features, which when taken with the PSA value, provide an estimate of the probability of extracapsular extension in the individual case. Quantitative measures of angiogenesis by OMVD seem to add further valuable staging information.
CT scanning and MRI have been disappointing as staging tools, although recent reports using endorectal MRI technology is more encouraging. Bone scanning is now only recommended in those with PSA values b10 ng/ml or those with high Gleason scores and/or skeletal symptoms since this investigation in patients with lower values are almost always negative.
Immunoscintigraphy is currently in its infancy but holds some promise. Laparoscopic lymph node sampling may be considered in those relatively few patients with either poorly differentiated tumours and/or PSA values b 20 ng/ml who, by virtue of their life expectancy, are otherwise candidates for radical therapy.
The challenge for the future is to further enhance the precision of prostate cancer staging. This will serve two important purposes: ®rstly to reduce the number of patients undergoing procedures that in fact carry little prospect of rendering them disease free, and secondly to enhance the results of potentially curative therapies by accurately targeting them at those most likely to bene®t.
